Boston Scientific 's ( BSX ) CEO Mike Mahoney on Q3 2014 Results - Earnings Call Transcript
Boston Scientific reported strong third-quarter performance, and we have increased our fair value estimate to $12 per share from $10 after incorporating
Oct 22 (Reuters) - Boston Scientific Corp on Wednesday posted a third-quarter profit on increased sales of its implantable heart devices and raised its full-year revenue outlook, sending its shares up nearly 4 percent.
for several years thanks to more clinical evidence suggesting overstated clinical benefits, competitors such as Boston Scientific and Medtronic have been better able to navigate choppy waters with new innovation. Indeed, Boston's third-quarter
Boston Scientific ( BSX ) Q3 2014 Results - Earnings Call Webcast
Oct 22 (Reuters) - Boston Scientific Corp on Wednesday posted a third-quarter profit in line with analysts' expectations on stronger sales of its key implantable heart devices.
Boston Scientific revenues up 6%, lowers GAAP EPS guidance
Boston Scientific EPS in-line, beats on revenue
ABB , ABT , ANGI , APH , BA , BABY , BEAV , BIIB , BPOP , BSX , DOW , EMC , EVR , FDML , FNB , GD , GNTX , GRA , HCBK , ICLR , IPG , IR , KNX , LL , MDCO , MKTX , NOC , NSC , NTRS , NYCB , OC , PII , R , SEIC , SLGN , SPG , SWK , TMO , TUP , USB , WIT , WRLD , XRX Post your comment!
OTCQX:CYNAF ) (NASDAQ: IPXL ) ( OTCQB:TTNP ) ( OTCQB:SGTH ) (NYSE: TEVA ) (NASDAQ: ADMS ) (NASDAQ: PRAN ) (NASDAQ: CHTP ) (NASDAQ: PRTA ) (NASDAQ: FOLD ) (NASDAQ: AVNR ) (NYSE: BSX ) (NYSE: MRK ) Post your comment!